Search

You searched for "cysts"

565 results found

Demanding cases or nightmares in uro-oncology? May/Jun 2022

3 May 2022 | | URO - Urologic Oncology
Delayed diagnosis of testicular cancer Testicular cancer is considered rare in the general population but is the most common cancer affecting males between 24 and 49 years. The diagnosis of testicular cancer depends on physical examination, ultrasound findings and tumour...

So you want to be a urologist?

1 March 2017 | | URO - Core Urology
Urology is a varied, innovative and friendly speciality and it is easy to see why so many people are attracted to it. The article below is designed to help all doctors wishing to apply for an ST3 post get the...

Robotic Urology Fellowship at UCLH

1 May 2016 | | URO - Core Urology
In November 2014, approaching my final year of training (ST7) in the West of Scotland (WoS) and just recently armed with my FRCS (Urol), I was at a crossroad in my clinical career. I was keen to pursue a consultant...

The Lister Royal College of Surgeons of England / BAUS Accredited Robotic Urological Fellowship Programme

1 September 2015 | | URO - Core Urology
Robotic fellowship training in the UK – overview Robotic surgery has increased in popularity since its introduction in 2003. Its validation in a growing number of operative procedures has increased its acceptance nationwide and its usage is becoming widespread. Initial...

A negative ureteroscopy for stone disease: is it acceptable and is it avoidable?

1 September 2018 | | URO - Endourology & Stones
Urinary tract stone disease and the consequent demand for endoscopic intervention in the upper urinary tract is an increasing phenomenon [1]. Although ureteroscopy is generally considered to be associated with low morbidity [2], risks do exist. Recognised complications include urothelial...

Bladder carcinoma MRI

1 September 2018 | | URO - Urologic Oncology, URO - Uroradiology
Bladder malignancy is one of the commonest malignancies of the renal tract, accounting for approximately 6% of male malignancy and 2% of female malignancy. The incidence increases with patient age with 70% of patients being over the age of 65...

Management of stage 1 non-seminomatous germ cell tumours

1 November 2014 | | URO - Urologic Oncology
Testicular cancer (TC) is the most successfully treated solid tumour, achieving a cure rate of 90-95% [1-3]. Testicular cancer is relatively rare with an incidence of 2207 cases in the UK in 2014 [4] and yet is the most common...

Neuroendocrine bladder tumour

5 February 2025 | | URO - Urologic Oncology
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...

OCERT: a new multi-specialty project to standardise robotic surgical training

3 June 2020 | | URO - Urologic Oncology, URO - Technology
Since its introduction by Dr William Osler in 1890 to the Board of Trustees at John Hopkins Hospital [1], the Halstedian ‘See one, do one, teach one’ has represented a guideline for surgeons worldwide, both for open and laparoscopic surgery,...

Prostate cancer: Black men more likely to be diagnosed at later stages

9 January 2025 | Charities, Research & Development
Latest data shows Black men have higher rates of stage 3 or stage 4 prostate cancer diagnoses compared with white men. Black men diagnosed at a later stage in their 60s are 14% less likely to get NICE approved treatment...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

1 May 2017 | | URO - Urologic Oncology
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

Focal therapy for prostate cancer – ready for prime time?

1 November 2016 | | URO - Basic Science Research, URO - Urologic Oncology
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...